Product image of Metojectpen (Methotrexate) supplied by GNH India

Metojectpen

Active Ingredient:
Methotrexate
Origin:
EU

Metojectpen (Methotrexate)

Methotrexate, the active ingredient in Metojectpen, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for systemic use. It is employed to manage autoimmune disorders and certain malignancies in adult patients.
GNH India supplies Metojectpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate is used across several disease families, primarily as an immunomodulator and antineoplastic agent.

  • Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
  • Psoriasis: decreases skin cell proliferation and improves plaque lesions.
  • Severe eczema: mitigates severe inflammatory skin eruptions.
  • Certain leukemias and lymphomas: interferes with malignant cell replication.
  • Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.
  • Ectopic pregnancy: facilitates medical management by inhibiting trophoblastic growth.

How It Works

  • Methotrexate inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate and thereby disrupting folate‑dependent synthesis of purines and thymidylate. This impairs DNA, RNA and protein synthesis, leading to reduced proliferation of rapidly dividing immune cells and malignant cells, and ultimately modulating inflammatory pathways.

Side Effects

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea or vomiting: mild gastrointestinal upset.
  • Fatigue: generalized tiredness.
  • Mouth sores: ulceration of oral mucosa.
  • Elevated liver enzymes: mild hepatic irritation.
  • Low blood counts: mild leukopenia or anemia.
  • Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects

  • Severe liver toxicity: potential hepatitis or fibrosis.
  • Pulmonary fibrosis: interstitial lung disease with dyspnea.
  • Myelosuppression: profound neutropenia or pancytopenia.
  • Renal impairment: acute kidney injury.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Methotrexate requires careful monitoring and patient education to minimise risks.

  • Pregnancy contraindication: drug is teratogenic and must not be used in pregnancy (Category X).
  • Liver monitoring: perform baseline and periodic liver function tests.
  • Renal function: assess creatinine clearance before initiation and during therapy.
  • Blood counts: conduct regular complete blood counts to detect myelosuppression.
  • Drug interactions: avoid concurrent use with high‑dose NSAIDs or other folate antagonists.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methotrexate interacts with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (high‑dose NSAIDs): increase methotrexate toxicity.
  • Proton pump inhibitors (omeprazole, esomeprazole): may elevate serum levels.
  • Trimethoprim‑sulfamethoxazole: augments risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

  • Azathioprine or mycophenolate: additive immunosuppression.
  • Penicillins (high‑dose): may reduce renal clearance of methotrexate.
  • Live vaccines: risk of infection due to immunosuppression.

Frequently Asked Questions

Metojectpen contains methotrexate and is indicated for rheumatoid arthritis, psoriasis, severe eczema, certain leukemias and lymphomas, gestational trophoblastic disease, and ectopic pregnancy. In each case the drug helps control disease activity by reducing abnormal cell proliferation or immune‑mediated inflammation.

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This inhibition curtails the growth of rapidly dividing cells, such as immune cells involved in inflammation and malignant cells in cancers, thereby providing therapeutic benefit.

The dosage of Metojectpen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified healthcare professional should determine the appropriate dose and administration schedule.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal harm and birth defects. It is contraindicated in pregnancy and should be discontinued well before conception. Breastfeeding is also not recommended while using methotrexate.

To place an order, submit an enquiry on the Metojectpen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Metojectpen is a subcutaneous formulation of methotrexate, offering rapid absorption and consistent bioavailability compared with oral tablets, which can have variable uptake. Compared with other injectable brands, it provides a similar efficacy profile while allowing flexible dosing under medical supervision.

Metojectpen should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Metojectpen is given by subcutaneous injection, typically into the abdomen or thigh. The injection should be performed by a trained healthcare professional using aseptic technique, following the dose and schedule prescribed by the treating physician.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound myelosuppression leading to infection or bleeding, and renal impairment. Patients should be monitored regularly for liver enzymes, lung function, blood counts and kidney function to detect these complications early.

Metojectpen is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, known hypersensitivity to methotrexate, and patients with significant renal impairment that would limit drug clearance. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT